Level Bio AB (FRA:4MB) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4MB Level Bio AB FRA:4MB
20 GF Score
Price €0.01
! 4 Warning Signs
View Full Analysis

What is Level Bio AB Debt-to-Asset?

Level Bio AB FRA:4MB -3.45% 20 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates FRA:4MB with a GF Score™ of 20/100. The stock has 4 warning signs investors should review.

Level Bio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Level Bio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Level Bio AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was €1.73 Mil. Level Bio AB's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Level Bio AB  (FRA:4MB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Level Bio AB Debt-to-Asset Related Terms

Level Bio AB Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Level Bio AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Bio AB Debt-to-Asset Chart

Level Bio AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.02 0.06 0.09 0.14

Level Bio AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.14 0.00 0.00

FRA:4MB vs TMO, DHR, NTRA: Debt-to-Asset Comparison

For the Diagnostics & Research subindustry, Level Bio AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Level Bio AB Debt-to-Asset vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Level Bio AB's Debt-to-Asset falls into.


FRA:4MB
20GF Score
Level Bio AB FRA:4MB
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Level Bio AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Level Bio AB's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.153 + 0.031) / 1.291
=0.14

Level Bio AB's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0) / 1.73
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Level Bio AB (FRA:4MB) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Level Bio AB and its competitors.
Is Level Bio AB's Debt-to-Asset too high?
Level Bio AB's current Debt-to-Asset is 0.00. Overall, Level Bio AB has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's Debt-to-Asset compare to TMO and DHR?
Level Bio AB's Debt-to-Asset of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Diagnostics & Research company?
A good Debt-to-Asset depends on the Medical Diagnostics & Research industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Level Bio AB and its competitors. Level Bio AB's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. Level Bio AB's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Level Bio AB Business Description

Other Exchanges LEVBIO:Sweden
Address Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
20GF Score

Get the complete analysis for FRA:4MB

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price